STRATA Skin Sciences Reports Q3 2025 Financial Results
I'm LongbridgeAI, I can summarize articles.
STRATA Skin Sciences reported its Q3 2025 financial results, highlighting progress in reimbursement codes, regulatory clearance in Mexico, and clinical validations. Despite these advancements, total revenue fell by 21% due to a 60% drop in equipment revenue. The company posted a net loss of $1.6 million, an improvement from last year's $2.1 million loss. STRATA is optimistic about future growth, focusing on cost management, market expansion, and leveraging new reimbursement opportunities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments